Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longboard Pharmaceuticals (LBPH)
NASDAQ:LBPH
RESEARCH TOOLSreports
Longboard Pharmaceuticals (LBPH) Stock Price & Analysis
205 Followers
LBPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $31.80
Previous Close$30.92
Volume1.64M
Average Volume (3M)408.69K
Market Cap
$1.20B
Enterprise Value$885.11M
Total Cash (Recent Filing)$321.04M
Total Debt (Recent Filing)$3.98M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Aug 01, 2024EPS Estimate
-$0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.26
Shares Outstanding38,880,054
10 Day Avg. Volume312,663
30 Day Avg. Volume408,689
Standard Deviation0.49
R-Squared0.01
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)19.77
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-18.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-14.30
Forecast
1Y Price Target
$55.57Price Target Upside80.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Longboard Pharmaceuticals News
PremiumCompany Announcements
Longboard Pharmaceuticals Advancing DEE Treatment Trials
PremiumCompany Announcements
Longboard Pharmaceuticals Advances with Promising Seizure Treatment Study
Bulls Say, Bears Say
Bulls Say
Clinical ValidationThe PACIFIC data provide clinical validation of bexicaserin’s differentiated mechanism of action as a potentially safer, more effective serotonergic agonist approach for the treatment of multiple developmental and epileptic encephalopathies.
Efficacy DataThe revised primary efficacy endpoint data surpassed the original readout showing further improvements in seizure reductions and did not change the reported safety results.
Regulatory DiscussionsAnalyst reiterates Buy rating and expects a positive outcome from the discussions with the FDA and other regulatory agencies, which can further de-risk the program and Longboard’s epilepsy franchise more broadly.
Bears Say
Clinical TrialsInvestors have been focused on the titration scheme for bexicaserin and implications for dropout rate in Ph3 trials, given 11/43 participants randomized to bexicaserin in PACIFIC discontinued.
Product PipelineThere is currently minimal credit in the stock for LP659.
Stock PerformanceLBPH shares were down in Monday’s trading, against a backdrop of broader XBI weakness.
---
Ownership Overview
0.10% Insiders
26.07% Mutual Funds
70.58% Other Institutional Investors
3.26% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LBPH FAQ
What was Longboard Pharmaceuticals’s price range in the past 12 months?
Longboard Pharmaceuticals lowest stock price was $3.60 and its highest was $31.80 in the past 12 months.
What is Longboard Pharmaceuticals’s market cap?
Currently, no data Available
When is Longboard Pharmaceuticals’s upcoming earnings report date?
Longboard Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is in 29 days.
How were Longboard Pharmaceuticals’s earnings last quarter?
Longboard Pharmaceuticals released its earnings results on May 02, 2024. The company reported -$0.42 earnings per share for the quarter, beating the consensus estimate of -$0.491 by $0.071.
Is Longboard Pharmaceuticals overvalued?
According to Wall Street analysts Longboard Pharmaceuticals’s price is currently Undervalued.
Does Longboard Pharmaceuticals pay dividends?
Longboard Pharmaceuticals does not currently pay dividends.
What is Longboard Pharmaceuticals’s EPS estimate?
Longboard Pharmaceuticals’s EPS estimate is -$0.44.
How many shares outstanding does Longboard Pharmaceuticals have?
Longboard Pharmaceuticals has 33,609,300 shares outstanding.
What happened to Longboard Pharmaceuticals’s price movement after its last earnings report?
Longboard Pharmaceuticals reported an EPS of -$0.42 in its last earnings report, beating expectations of -$0.491. Following the earnings report the stock price went down -6.269%.
Which hedge fund is a major shareholder of Longboard Pharmaceuticals?
Among the largest hedge funds holding Longboard Pharmaceuticals’s share is Farallon Capital Management, L.L.C.. It holds Longboard Pharmaceuticals’s shares valued at 125M.
---
Longboard Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$55.57 (80.77% Upside)
$55.57 (80.77% Upside)
Blogger Sentiment
Neutral
LBPH Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 9.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
321.25%
12-Months-Change
Fundamentals
Return on Equity
-30.04%
Trailing 12-Months
Asset Growth
311.21%
Trailing 12-Months
Company Description
Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.
---
LBPH Earnings Call
Q4 2023
0:00 / 0:00
---
LBPH Stock 12 Month Forecast
Average Price Target
$55.57
▲(80.77% Upside)
Technical Analysis
Best Analysts Covering LBPH
1 Year
1 Year Success Rate
17/17 ratings generated profit
1 Year Average Return
+158.12%
reiterated a buy rating 22 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +158.12% per trade.
---